Psychedelics change how you read faces. That may help alleviate anxiety and depression.

Even more intriguing is the reason: recognizing facial expressions.

  • A new systematic review states that serotonergic hallucinogens help users recognize emotions in facial expressions.
  • Sufferers of anxiety and depression often only read negative emotions in other people's faces, adding to their malaise.
  • While more research is needed, psychedelics could prove to be a powerful agent in battling mental health disorders.


If you want to know what someone is thinking, don't listen to their words. Instead, watch their face. Recognition of emotions in facial expressions (REFE) is one of our animal superpowers. Expressions predate language as a major form of communication and often tell a much more honest story than the string of sounds emerging from mouths.

Learning by watching someone's facial and bodily pantomimes plays an important role in our social heritage. Context matters as well. Plenty of room for error exists should you misdiagnose. Yet higher-order emotions, such as empathy, rely on understanding the experiences of others. This begins by comprehending facial expressions that you too have lived through.

This human trait is what makes a new systematic review of eight prior studies on psychedelics so interesting. Published in Therapeutic Advances in Psychopharmacology, a team at the University of Sao Paulo discovered that LSD and psilocybin reduce the user's recognition of negative facial expressions thanks to modulated amygdala activity.

For those that experience trouble reading emotional states, such an intervention could be a boon. Previous research shows that sufferers of anxiety and mood disorders have trouble reading facial expressions.

With anxiety disorder—a mental condition I spent a quarter-century battling—an intensive focus on negative emotions overrides other forms of expression. The sufferer internalizes negative cues, reinforcing their overactive nervous system. Recognizing positive emotional cues becomes a chore. You question everyone's motives, and they always skew adversarial, at least in your mind.

How LSD and shrooms could help treat anxiety, addiction and depression

Fortunately, improving REFE has a therapeutic effect. Depression, for example, is alleviated faster through REFE than antidepressants. Since pharmaceuticals often have damaging long-term consequences, using a natural, skillful intervention (such as learning to better read faces) is low-risk, high-reward medicine.

The authors write that while MDMA has been shown to improve REFE, so does a class of serotonergic hallucinogens that act on the brain's serotonin system: LSD, psilocybin (mushrooms), DMT (in ayahuasca or its more fast-acting isolated form), and mescaline. As tryptamine derivatives, these substances bind to serotonin-1a receptors (resulting in a feeling of contentment) and serotonin-2a receptors (resulting in the "mystical experience"). This potent combination results in both an alleviation from the drudgery of self while also boosting sensations of satisfaction and ease.

The therapy is holistic—it's no longer only about you. A sense of universality of shared experience emerges. Postdoctoral fellow Rafael Guimarães dos Santos says of the study:

"Altering emotional processing by modifying facial emotion recognition could be one of the mechanisms involved in the therapeutic potentials of ayahuasca and other serotonergic hallucinogens."

Collecting a total of 62 studies that fit their search criteria, dos Santos and team settled on eight for their review. While the initial data collection included research on a variety of psychedelics, they ended up using only studies that investigated LSD or psilocybin.

Photo by Joe Amon/MediaNews Group/The Denver Post via Getty Images

Mazatec psilocybin mushrooms dried and ready for consumption May 14, 2019 in Denver, Colorado.

There were a few issues, causing the team to add the disclaimer that their review might not provide clinical significance. The studies reviewed were small; some did not use placebo (although, to be fair, you know if you receive a placebo during a study on psychedelics). Still, the authors conclude:

"The studies reviewed showed that a single dose or a few doses of LSD or psilocybin was associated with a modified pattern of recognition of negative emotions that could be interpreted as beneficial, since several of these studies showed that these modifications were correlated with increases in positive mood and/or anxiolytic and antidepressant effects."

Since there is a correlation between depression and increased responses in the amygdala, your brain's fight-flight-freeze center, that serotonergic hallucinogens tamp down the negative response mechanism is worth noting. Other brain regions are also influenced by psychedelics, but the loosening of depression and anxiety appears to be centered in that almond-shaped set of neurons.

Another explanation might be that psychedelics inspire in us a sense of awe. They can certainly be overwhelming, yet they are also humbling. Instilling humility appears to be a primary therapeutic effect of serotonergic hallucinogens, which is likely why they have shown efficacy in treating addiction.

Feeling part of a larger whole is the opposite of anxiety, which can reach existential heights in severe cases. Psychedelics appear disorienting to the novice, yet with time and guidance they are quite instructive. American society is catching on to their potential, with Denver decriminalizing mushrooms and Oakland doing the same for all "natural psychedelics."

Quieting the fear response is an important therapeutic agent in many diseases. We know that, for many people, current antidepressant regimens are not working. It's time for larger-scale studies to give psychedelics the chance they deserve.

--

Stay in touch with Derek on Twitter and Facebook.

Should you defend the free speech rights of neo-Nazis?

Former president of the ACLU Nadine Strossen discusses whether our society should always defend free speech rights, even for groups who would oppose such rights.

Sponsored by Charles Koch Foundation
  • Former ACLU president Nadine Strossen understands that protecting free speech rights isn't always a straightforward proposition.
  • In this video, Strossen describes the reasoning behind why the ACLU defended the free speech rights of neo-Nazis in Skokie, Illinois, 1977.
  • The opinions expressed in this video do not necessarily reflect the views of the Charles Koch Foundation, which encourages the expression of diverse viewpoints within a culture of civil discourse and mutual respect.
Keep reading Show less

It’s just a sheet of glass. With AI.

A new paradigm for machine vision has just been demonstrated.

Image source: aleknext/Shutterstock
Technology & Innovation
  • Scientists have invented a way for a sheet of glass to perform neural computing.
  • The glass uses light patterns to identify images without a computer or power.
  • It's image recognition at the speed of light.
Keep reading Show less

New alternative to Trump's wall would create jobs, renewable energy, and increase border security

A consortium of scientists and engineers have proposed that the U.S. and Mexico build a series of guarded solar, wind, natural gas and desalination facilities along the entirety of the border.

Credit: Purdue University photo/Jorge Castillo Quiñones
Politics & Current Affairs
  • The proposal was recently presented to several U.S. members of Congress.
  • The plan still calls for border security, considering all of the facilities along the border would be guarded and connected by physical barriers.
  • It's undoubtedly an expensive and complicated proposal, but the team argues that border regions are ideal spots for wind and solar energy, and that they could use the jobs and fresh water the energy park would create.
Keep reading Show less

Elon Musk’s Neuralink unveils device to connect your brain to a smartphone

"A monkey has been able to control a computer with its brain," Musk said, referring to tests of the device.

Neuralink
Technology & Innovation
  • Neuralink seeks to build a brain-machine interface that would connect human brains with computers.
  • No tests have been performed in humans, but the company hopes to obtain FDA approval and begin human trials in 2020.
  • Musk said the technology essentially provides humans the option of "merging with AI."
Keep reading Show less